secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silk Road Medical Inc (—)
CIK:        0001397702
Form:       8-K
Filed at:   2024-04-30T23:59:59+00:00
Accession:  0001397702-24-000029
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silk Road Medical Q1 2024 revenue $48.5M (+21% YoY); net loss narrows to $14.1M
-------------------------------------------------------------------------------

- Revenue $48.5M, up 21% YoY driven by increased TCAR adoption.
- Gross margin 75%, up from 69% YoY due to favorable production variances.
- Net loss $14.1M ($0.36/share) vs $16.5M ($0.43/share) in Q1 2023.
- Adjusted EBITDA loss improved to $3.9M from $7.4M in Q1 2023.
- CEO cites commercial progress and steps toward sustainable profitability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1397702/000139770224000029/0001397702-24-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1397702/000139770224000029/silk-20240430x8k.htm
  HTML page:      https://secwatch.observer/filing/0001397702-24-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer